The heightened awareness has been fuelled by recent reports of contaminated cough syrups that contained toxic industrial chemicals like diethylene glycol (DEG) and ethylene glycol (EG). Reflecting this renewed focus on consumer safety, the Government of India has introduced amendments to the Drugs & Cosmetics Rules to strengthen regulatory oversight of syrup formulations.
This growing focus on safety and quality is prompting more consumers to choose Ayurvedic cough remedies. While conventional cough syrups are formulated using pharmaceutical active ingredients, Ayurvedic cough syrups are made with time-tested medicinal herbs such as Tulsi, Mulethi, Saunth and Banafsha, ingredients that have been used in Ayurveda for generations to soothe the throat, support respiratory health and provide relief from cough. This familiarity with natural herbal ingredients validated through modern scientific studies is increasingly driving consumer confidence in Ayurvedic formulations.
As consumer expectations evolve, trust, safety and efficacy are driving a growing preference for Ayurvedic formulations that combine the goodness of traditional herbs with the reassurance of modern scientific research.
Consumers should always purchase medicines from reputable sources and use them as directed on the label and preferably as recommended by a registered medical practitioner.
This article has been authored by Vaidya Sujata Choudhary.


Kumar Sanu, Shankar Mahadevan and Javed Ali Bring the Festive Cheer to Sa Re Ga Ma Pa 2026’s Diwali Special
Kumar Sanu surprises contestant Durgesh; says, “I will send a TV to your home so that your mother and father can watch you on Sa Re Ga Ma Pa”
Great Value Realty Brings On Sanju Bose Landscape Architects to Shape Outdoor Living at Ekanam, 107
Ram Kamal Mukherjee wins Best Director at the 11th International Indian Film Festival of Toronto for the Lokkhikantopur Local
Avis India Expands Premium Group Mobility Portfolio with Launch of Customised Force Urbania Vans
NBFC-MFIs Lead India’s Microfinance Market as Portfolio Share Reaches 44.7%: CRIF MicroLend